Bora Lim

43PUBLICATIONS
378CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markersLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Aug 21, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

|Jul 16, 2026
Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

|Jul 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

|May 13, 2026
Ecotypes of triple-negative breast cancer in response to chemotherapy.

|Oct 21, 2025
A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease).

Bora Lim, Angela Marx, Megumi Kai

|Aug 27, 2025
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

Ze-Yi Zheng, Anran Chen, Eric J Jaehnig

Pageof 8

Frequent Collaborators

12 joint publications

Naoto Ueno

9 joint publications

Debu Tripathy

5 joint publications

Jonathan T Lei

5 joint publications

Jason White